



## NEWS

### Press Releases

For Immediate Release

## ANTHERA PHARMACEUTICALS COMPLETES INITIAL PUBLIC OFFERING

**HAYWARD, CA – March 4, 2010** – Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH), a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced the completion of its initial public offering of six million shares of common stock at a price of \$7.00 per share. The net proceeds of the offering to Anthera, after deducting underwriting discounts and commissions and estimated offering expenses payable by Anthera, were approximately \$36.7 million. In addition, Anthera has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any. The sole book-running manager of the offering is Deutsche Bank Securities Inc. Piper Jaffray & Co. is a co-lead manager of the offering and Cowen and Company, LLC and Merriman Curhan Ford & Co. are co-managers of the offering.

Concurrently with the closing of the offering, Anthera completed a private placement of an aggregate of 2,598,780 shares of common stock to certain of its existing investors at a price of \$6.58 per share, which is the initial public offering price per share less underwriting discounts and commissions, which will result in net proceeds to Anthera of an additional \$17.1 million. Total net proceeds to Anthera of the initial public offering and the concurrent private placement totaled approximately \$53.8 million.

In addition, Anthera issued an aggregate of 531,914 shares of common stock to Eli Lilly and Shionogi and Co., Ltd in satisfaction of a \$3.5 million milestone payment related to the initiation of the VISTA-16 trial for A-002, which Anthera expects to initiate in the near future.

A registration statement relating to the shares of Anthera's common stock offered in the initial public offering has been declared effective by the Securities and Exchange Commission. The initial public offering is being made solely by means of a prospectus. A copy of the final prospectus, when available, can be obtained by contacting: Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: [prospectusrequest@list.db.com](mailto:prospectusrequest@list.db.com).

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

#### **About Anthera Pharmaceuticals**

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 ready clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA<sub>2</sub>. Elevated levels of sPLA<sub>2</sub> have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease, or CAD. Anthera's Phase 2 ready product candidate, A-623, targets elevated levels of B-lymphocyte stimulator, or BLYS, which has been associated

with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus. Anthera has worldwide rights to its product candidates, with the exception of Japan, where Shionogi & Co., Ltd. retains commercial rights to its sPLA<sub>2</sub> product candidates.

**Forward-Looking Statements**

This press release contains forward-looking statements. Forward-looking statements relate to future events. These statements are only predictions. The outcome of the events described in these forward-looking statements is subject to risks and uncertainties. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and the timing of events and circumstances and actual results could differ materially from those projected in the forward looking statements.

CONTACT: Juliane Snowden of Burns McClellan, Inc., [jsnowden@burnsmc.com](mailto:jsnowden@burnsmc.com) or 212.213.0006.